Early pancreatic cancer data give Clovis a new path in PARP market

Early pancreatic cancer data give Clovis a new path in PARP market

Submitted by admin on April 2, 2019 - 4:22pm
Source: 
Biopharma Dive
News Tags: 
pancreatic cancer
Clovis Oncology
AstraZeneca
PARP inhibitors
AACR
Rubraca
Lynparza
Headline: 
Early pancreatic cancer data give Clovis a new path in PARP market
snippet: 

Yet pharma rival AstraZeneca remains ahead, having posted positive Phase 3 data in pancreatic cancer earlier this year.

Do Not Allow Advertisers to Use My Personal information